Xeljanz has Strong Launch in Arthritis, May See Greater than Expected first-line use

[Anonymous]

We fuc*in rock! No one does it better than Pfizer baby!!!!!!!!!!!

http://www.bloombergbriefs.com/files/HealthcareFinance_021113_page8.pdf
Pfizer’s novel rheumatoid arthritis drug (RA) Xeljanz has had a strong launch in the U.S. Initial analysis of prescription data from Symphony Health Solutions suggests that Xeljanz use will not be limited to patients who have an inadequate response to TNF inhibitors, which currently dominate the market.

Additional data on a higher dose and use in an earlier stage of treatment may further improve launch metrics. The drug may also soon receive an opinion regarding EU approval.

Prescription data analyzed by Bloomberg Industries show that Xeljanz has had
a better launch than other drugs recently approved for the indication. Unlike other
mainstay therapies for RA, which are given as a subcutaneous injection or
through an infusion, Xeljanz is available as a pill.

 

[Anonymous]

Re: Xeljanz has Strong Launch in Arthritis, May See Greater than Expected first-line

We fuc*in rock! No one does it better than Pfizer baby!!!!!!!!!!!

http://www.bloombergbriefs.com/files/HealthcareFinance_021113_page8.pdf
Pfizer’s novel rheumatoid arthritis drug (RA) Xeljanz has had a strong launch in the U.S. Initial analysis of prescription data from Symphony Health Solutions suggests that Xeljanz use will not be limited to patients who have an inadequate response to TNF inhibitors, which currently dominate the market.

Additional data on a higher dose and use in an earlier stage of treatment may further improve launch metrics. The drug may also soon receive an opinion regarding EU approval.

Prescription data analyzed by Bloomberg Industries show that Xeljanz has had
a better launch than other drugs recently approved for the indication. Unlike other
mainstay therapies for RA, which are given as a subcutaneous injection or
through an infusion, Xeljanz is available as a pill.

Mainly just contract reps out there doing this, ain't it?

 

[Anonymous]

Re: Xeljanz has Strong Launch in Arthritis, May See Greater than Expected first-line

Mainly just contract reps out there doing this, ain't it?

You Pfizer people have such an over-inflated opinion of yourselves.
For the last 15 years Pfizer has ridden on the backs of "others".

Parke Davis is the reason for Lipitor
Searle is the reason for Celebrex
Parke Davis is the reason for Lyrica

Not sure what Wyeth has contributed of significance.
Not sure what King has contributed of significance.

But I am sure Pfizer has contributed nothing for quite some time.
Get over yourself, Pfizer. You're not "all that"

 

[Anonymous]

Re: Xeljanz has Strong Launch in Arthritis, May See Greater than Expected first-line

You Pfizer people have such an over-inflated opinion of yourselves.
Not sure what Wyeth has contributed of significance.

Prevnar is only the #1 Pfizer product by revenue post-Lipitor LOE at around $4 billion a year.
Xeljanz team came from Wyeth on Enbrel-Amgen co-promote.
Premarin brings in nearly $1 billion a year.
Many others, but what the hell?

 

[Anonymous]

Re: Xeljanz has Strong Launch in Arthritis, May See Greater than Expected first-line

Mainly just contract reps out there doing this, ain't it?

Our contract reps f-in rock! They are responsible for the sales and deserve all the credit. As soon as they really blow their quotas out of the water, the REAL Pfizer reps will swoop in and take all the credit for their work while the Publicius reps move on to selling generic Nexium for astraZeneca! Now that is how you USE a contract sales force.

 

[Anonymous]

Re: Xeljanz has Strong Launch in Arthritis, May See Greater than Expected first-line

Our contract reps f-in rock! They are responsible for the sales and deserve all the credit. As soon as they really blow their quotas out of the water, the REAL Pfizer reps will swoop in and take all the credit for their work while the Publicius reps move on to selling generic Nexium for astraZeneca! Now that is how you USE a contract sales force.

Actually, the more likely scenario is that corporate sees that a contract force making less than 1/2 of a "Pfizer Rep", can move the product just as well. In that case, expect more reps to be added to this contract, and expect a new team that will get Elquis.

 

[Anonymous]

Re: Xeljanz has Strong Launch in Arthritis, May See Greater than Expected first-line

You Pfizer people have such an over-inflated opinion of yourselves.
For the last 15 years Pfizer has ridden on the backs of "others".

Parke Davis is the reason for Lipitor
Searle is the reason for Celebrex
Parke Davis is the reason for Lyrica

Not sure what Wyeth has contributed of significance.
Not sure what King has contributed of significance.

But I am sure Pfizer has contributed nothing for quite some time.
Get over yourself, Pfizer. You're not "all that"

...and BMS is the reason for Eliquis.

Pfizer used to have some smoking' reps though. That sure helped.